Product Information
PF-06649283 is a drug that binds to the BACE1 enzyme and inhibits its activity. It is currently being investigated as a potential treatment for Alzheimer's disease, although it has not yet been approved by the FDA. PF-06649283 binds to the c-terminal domain of BACE1 and prevents it from degrading amyloid precursor protein (APP). This results in an increase in amyloid beta peptides, which are thought to be involved in the pathogenesis of Alzheimer's disease. The drug also inhibits other proteases such as cathepsin D, which may contribute to its therapeutic effects. In addition, PF-06649283 has been shown to activate microglia cells in primary hippocampal cultures. These cells have been implicated in neurodegenerative diseases such as Parkinson's and Alzheimer's disease and have been shown to produce inflammatory cytokines that can destroy neurons.
PF-06649283 also blocks cell surface receptors on cerebellar granule
Chemical properties
Technical inquiry about: 3D-WPC58517 PF-06649283
If you want to request a quotation or place an order, please instead add the desired products to your cart and then request a quotation or order from the cart. It is faster, cheaper, and you will be able to benefit from the available discounts and other advantages.
